Loading...
XSTO
ACE
Market cap58mUSD
Jun 05, Last price  
4.86SEK
1D
4.07%
1Q
62.54%
IPO
-83.42%
Name

Ascelia Pharma AB

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
19.89%
Rev. gr., 5y
%
Revenues
0k
Net income
-80m
L-26.77%
-24,392,000-37,134,000-39,905,000-98,697,000-125,903,000-131,222,000-109,288,000-80,029,000
CFO
-63m
L-50.44%
-20,958,000-30,333,000-36,918,000-85,527,000-116,559,000-125,263,000-126,792,000-62,844,000
Earnings
Aug 13, 2025

Profile

Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden.
IPO date
Mar 13, 2019
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122019‑062018‑062017‑06
Income
Revenues
Cost of revenue
69,462
112,527
117,782
Unusual Expense (Income)
NOPBT
(69,462)
(112,527)
(117,782)
NOPBT Margin
Operating Taxes
94
(319)
(1,933)
Tax Rate
NOPAT
(69,556)
(112,208)
(115,849)
Net income
(80,029)
-26.77%
(109,288)
-16.72%
(131,222)
4.22%
Dividends
Dividend yield
Proceeds from repurchase of equity
105,324
(89)
(84)
BB yield
-66.79%
0.08%
0.02%
Debt
Debt current
25,397
884
291
Long-term debt
172
1,236
677
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(49,687)
(19,735)
(148,587)
Cash flow
Cash from operating activities
(62,844)
(126,792)
(125,263)
CAPEX
(65)
Cash from investing activities
46
(65)
Cash from financing activities
115,187
(936)
(1)
FCF
(68,619)
(112,643)
(114,656)
Balance
Cash
75,256
21,855
149,555
Long term investments
Excess cash
75,256
21,855
149,555
Stockholders' equity
(643,780)
(604,420)
(497,889)
Invested Capital
748,121
679,808
679,231
ROIC
ROCE
EV
Common stock shares outstanding
54,001
33,720
33,668
Price
2.92
-13.35%
3.37
-77.44%
14.94
-49.95%
Market cap
157,683
38.76%
113,636
-77.41%
503,004
-48.87%
EV
107,996
93,901
354,417
EBITDA
(69,462)
(111,478)
(116,736)
EV/EBITDA
Interest
14
48
Interest/NOPBT